Bangying Su

Title: Bangying Su: Innovator in Therapeutic Interventions

Introduction

Bangying Su is a notable inventor based in Philadelphia, PA (US). He has made significant contributions to the field of therapeutic interventions, particularly in the context of diabetic complications. His innovative work focuses on metabolic pathways and their implications for health.

Latest Patents

Bangying Su holds a patent for "Compounds and methods for therapeutic intervention in preventing diabetic complications." This invention is based on the discovery of a metabolic pathway where a specific kinase converts fructose-lysine into fructose-lysine-3-phosphate in an ATP-dependent reaction. The resulting fructose-lysine-3-phosphate (FL3P) is then broken down to produce free lysine, inorganic phosphate, and 3-deoxyglucosone (3DG). The latter is a reactive protein-modifying agent that can lead to advanced glycation end-products (AGE-proteins), which are associated with diabetic complications. His patent discloses a class of compounds that inhibit the action of FL3P kinase, offering therapeutic methods to reduce the formation of AGE-proteins and mitigate diabetic complications.

Career Highlights

Bangying Su is affiliated with the Fox Chase Cancer Center, where he continues to advance his research and innovations. His work has the potential to significantly impact the treatment and management of diabetes, providing new avenues for therapeutic intervention.

Collaborations

Some of his notable coworkers include Truman R Brown and Francis Kappler, who contribute to the collaborative efforts in research and development at the Fox Chase Cancer Center.

Conclusion

Bangying Su's innovative work in therapeutic interventions highlights the importance of understanding metabolic pathways in addressing diabetic complications. His contributions through patents and research are paving the way for new treatment strategies in the field of diabetes.